CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Corcept Therapeutics's Net Income for the three months ended in Sep. 2024 was $47.2 Mil. Corcept Therapeutics's Revenue for the three months ended in Sep. 2024 was $182.5 Mil. Therefore, Corcept Therapeutics's net margin for the quarter that ended in Sep. 2024 was 25.86%.
The historical rank and industry rank for Corcept Therapeutics's Net Margin % or its related term are showing as below:
The historical data trend for Corcept Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Net Margin % | Get a 7-Day Free Trial | 30.73 | 29.96 | 30.74 | 25.24 | 22.00 |
Corcept Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Net Margin % | Get a 7-Day Free Trial | 25.39 | 23.16 | 18.91 | 21.67 | 25.86 |
For the Biotechnology subindustry, Corcept Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Corcept Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as
Net Margin | = | Net Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | 106.14 | / | 482.375 | |
= | 22.00 % |
Corcept Therapeutics's Net Margin for the quarter that ended in Sep. 2024 is calculated as
Net Margin | = | Net Income (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | 47.213 | / | 182.546 | |
= | 25.86 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (NAS:CORT) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Corcept Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
William Guyer | officer: Chief Development Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gary Charles Robb | officer: CHIEF FINANCIAL OFFICER | C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
Joseph Douglas Lyon | officer: Chief Accounting Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Sean Maduck | officer: See Remarks | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Hazel Hunt | officer: Chief Scientific Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph K Belanoff | director, officer: CHIEF EXECUTIVE OFFICER | 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Baker G Leonard Jr | director, 10 percent owner | 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005 |
Joshua M. Murray | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Atabak Mokari | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gregg H Alton | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Kimberly Park | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Andreas Grauer | officer: Chief Medical Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By Marketwired • 04-29-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 05-28-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-28-2024
By PRNewswire • 08-26-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 07-30-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.